Danske Bank’s Xeris Biopharma Holdings XERS Stock Holding History

Danske Bank’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25,000	Closed	-$18.3K	–	1594
2025 Q4	$18.3K	Hold	25,000	–	–	﹤0.01%	1216
2025 Q3	$35K	Buy	+25,000	New	+$166K	﹤0.01%	1087

Other funds holding XERS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Danske Bank's XERS Position: Q4 2024 in Review

Danske Bank sold out of Xeris Biopharma Holdings (XERS) in Q4 2024, closing a stake of 2 shares — an estimated $6 sold.

Danske Bank first reported a position in XERS in Q3 2024 and held it in 1 quarter. The position peaked at $6 in Q3 2024. 162 funds tracked by Wall St. Rank hold XERS as of Q4 2024.

Danske Bank reported no remaining Xeris Biopharma Holdings position as of Q4 2024 after selling out during the quarter.
Danske Bank sold 2 Xeris Biopharma Holdings shares in Q4 2024, an estimated $6.
Danske Bank first reported a position in Xeris Biopharma Holdings in Q3 2024 and held it in 1 quarter.
Danske Bank's Xeris Biopharma Holdings position peaked at $6 in Q3 2024.
162 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2024.

Based on Danske Bank's 13F filing for Q4 2024, filed 18 Mar 2026.